Kun for helsepersonell

Søk

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss

Menu

Close

Om ZaviceftaVirkningsmekanismePatogen dekningTidlig hensiktsmessig behandlingIDSA anbefalingØkonomiske holdepunkterSpørsmål og svar om ZAVICEFTAPasientprofilerHAP/VAP pasientcUTI pasientcIAI pasientPediatriske pasienterSpørsmål og svar - FAQsEffekt Real-world evidenceEffektdataSpørsmål og svar om effektSikkerhetSikkerhet hos voksneSikkerhet hos barn/ungdomSpørsmål og svar om sikkerhetDoseringDosering hos voksneDosering hos barn/ungdomSpørsmål og svar om dosering
IDSA anbefalingZAVICEFTA is recommended by IDSA guidance* as a preferred treatment option for MDR Gram-negative infections caused by CRE† and DTR–P. aeruginosa1‡


Listen to Professor Peter Hawkey

Professor of Clinical and Public Health Bacteriology at University of Birmingham, United Kingdom, talk about IDSA guidance, based upon his presentation 'Reviewing the IDSA guidance: treating Gram-negative infections in an era of multidrug resistance?’ Professor Hawkey goes into detail about the IDSA guidance including treatment recommendations for CRE, P. aeruginosa and ESBL.

Footnotes:

*The IDSA guidance recommends doses and infusion times for products that might be inconsistent with their approved prescribing information.1 Please check with your appropriate local authority for approved uses and indications. ZAVICEFTA (ceftazidime–avibactam) is not approved for combination therapy use in MBL-producing organisms. IDSA guidance on treatment recommendations pertaining to MBL-producing CRE are not discussed on this website and not recommended or endorsed by Pfizer.1,2 Treatment recommendations for CRE and DTR-P. aeruginosa infections assume that in vitro activity of preferred and alternative antibiotics has been demonstrated.1
†For infections outside the urinary tract, resistant to both ertapenem (i.e., ertapenem MICs ≥2 mcg/mL) and meropenem (i.e., meropenem MICs ≥4 mcg/mL), AND carbapenemase testing results either not available or negative.1
‡Defined as P. aeruginosa exhibiting non-susceptibility to all of the following: piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem-cilastatin, ciprofloxacin and levofloxacin.1
§The term cUTI refers to UTIs occurring in association with a structural or functional abnormality of the genitourinary tract, or any UTI in an adolescent or adult male. 1
Meropenem-vaborbactam, imipenem-cilastatin-relebactam and cefiderocol are also preferred treatment options.1
**Meropenem-vaborbactam and imipenem-cilastatin-relebactam are also preferred treatment options.1
††For pyelonephritis and complicated UTI when resistant to both ertapenem and meropenem (meropenem-vaborbactam imipenem-cilastatin-relebactam and cefiderocol are the other preferred treatment options here). 1
‡‡For infections outside the urinary tract when CRE resistant to both ertapenem and meropenem and carbapenemase testing results are either not available or negative (meropenem-vaborbactam and imipenem-cilastatin-relebactam are the other preferred treatment options). 1
§§For infections outside the urinary tract caused by CRE with carbapenemase production (for KPC, meropenem-vaborbactam and imipenem-cilastatin-relebactam are the other preferred treatment options. For OXA-48, ceftazidime-avibactam is the only preferred option).1
¶¶Ceftolozane-tazobactam, imipenem-cilastatin-relebactam, cefiderocol and a single-dose of an aminoglycoside are also preferred treatment options. 1
***Ceftolozane-tazobactam, imipenem-cilastatin-relebactam and cefiderocol are also preferred treatment options. 1
†††Ceftolozane-tazobactam and imipenem-cilastatin-relebactam are also preferred treatment options. 1
‡‡‡Ceftolozane-tazobactam and imipenem-cilastatin-relebactam are also recommended as a reasonable treatment option.1

Abbreviations:

CRE, carbapenem-resistant Enterobacterales; DTR, difficult-to-treat resistance; IDSA, Infectious Diseases Society of America; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamases; MDR, multidrug-resistant; OXA, oxacillinase; UTI, urinary tract infection. 

References:

Tamma PD, et al. Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. 2022. Available at: https://www.idsociety.org/practice-guideline/amr-guidance/ (last accessed October 2022).ZAVICEFTA. Summary of Product Characteristics, 2022.
Preparatomtale
PP-ZVA-NOR-0141 Mai 2023
Om ZAVICEFTA

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei